Reports Q4 revenue $1.06M, consensus $1.64M. Peter Beetham, interim CEO of Cibus (CBUS), commented, “2025 was a landmark year that validated our technology leadership and strategic vision. Our seven Rice partner customers continue to drive our near-term 2027 and 2028 commercial launch targets in our USA and LATAM geographic markets, which have the potential for more than $200 million annual addressable royalties at peak. In our Sustainable Ingredients program, we generated initial customer payments as we ramp up commercialization efforts for 2026. And, most recently, we were selected by the UK Government as a technology partner in its Farming Innovation Programme. Importantly, the regulatory environment we’ve been helping to shape for over a decade reached a critical inflection point with the EU’s political agreement on New Genomic Techniques legislation. This advancement and the recently activated Precision Breeding Act in the United Kingdom have prompted the recent UK investment in precision breeding innovation. Gene editing can no longer be called an experiment-it’s the present state of agricultural innovation, and Cibus is positioned ahead of this curve.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBUS:
- Cibus Global Inc options imply 19.8% move in share price post-earnings
- CBUS Upcoming Earnings Report: What to Expect?
- Cibus partners in project funded by UK Government’s Department of Environment
- Cibus Announces Underwritten Public Offering of Common Stock
- Cibus 13.3M share Spot Secondary priced at $1.50
